Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Invesco Solar ETF
TAN
The Technology Select Sector SPDR® Fund
XLK
4
VanEck Semiconductor ETF
SMH
5
United States Natural Gas
UNG
US Stock MarketDetailed Quotes
Xilio Therapeutics (XLO)
- 8.460
- -0.060-0.70%
Close May 29 16:00 ET
- 8.460
- 0.0000.00%
Post 16:10 ET
55.63MMarket Cap-3.71P/E (TTM)
8.500High8.090Low27.04KVolume8.470Open8.520Prev Close226.38KTurnover0.64%Turnover RatioLossP/E (Static)6.58MShares12.73952wk High0.77P/B35.86MFloat Cap6.46552wk Low--Dividend TTM4.24MShs Float391.300Historical High--Div Yield TTM4.81%Range %6.454Historical Low8.372Avg Price1Lot Size
XLO Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
XLO Orderflow
Unit: --
XLO Orderflow Trend
IntradayDayWeekMonth
No Data
Xilio Therapeutics (XLO) News
Xilio Therapeutics Reports Q1 Results
Xilio Therapeutics Files $250M Mixed Securities Shelf
Express News | Xilio Therapeutics Inc - May Offer up to $17.22 Mln Common Stock Under Sales Agreement With Leerink Partners - SEC Filing
Xilio Therapeutics Q1 EPS $(0.58) Beats $(0.66) Estimate, Sales $12.648M Beat $8.520M Estimate
Xilio Therapeutics | 10-Q: Quarterly report
Xilio Therapeutics | 8-K: Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics (XLO) Stock Forum
$Xilio Therapeutics (XLO.US)$ Xilio Therapeutics Inc - May Offer up to $17.22 Mln Common Stock Under Sales Agreement With Leerink Partners - SEC Filing
1
$Xilio Therapeutics (XLO.US)$ Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.66) by 12.12 percent. This is a 76.71 percent increase over losses of $(2.49) per share from the same period last year. The company reported quarterly sales of $12.648 million which beat the analyst consensus estimate of $8.520 million by 48.45 percent. This is a 331.67 percent increase...
1
$Xilio Therapeutics (XLO.US)$ Xilio Therapeutics (NASDAQ:XLO) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $(0.12) by 775 percent. This is a 128.93 percent increase over losses of $(2.80) per share from the same period last year. The company reported quarterly sales of $13.686 million which beat the analyst consensus estimate of $7.960 million by 71.93 percent. This is a 693.85 percent increase over sales of $1.724 million the same peri...
$Xilio Therapeutics (XLO.US)$ where r the evaluation review results? what happened today meeting? no updates?
3
3
$Xilio Therapeutics (XLO.US)$
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
....
Xilio Therapeutics (NASDAQ: XLO) reported late-breaking Phase ...
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
....
Xilio Therapeutics (NASDAQ: XLO) reported late-breaking Phase ...
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)